BiotechTube

HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromuscular Blockade

Conditions

Neuromuscular Blockade

Trial Timeline

Feb 1, 2026 → Jul 1, 2026

NCT ID
NCT07446309

About HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)

HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia) is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Neuromuscular Blockade. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07446309. Target conditions include Neuromuscular Blockade.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07446309Phase 2Recruiting

Competing Products

20 competing products in Neuromuscular Blockade

See all competitors
ProductCompanyStageHype Score
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
52
Placebo + Sugammadex + Esmeron®MerckPhase 2
52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
85
Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
85
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
23
Sugammadex + RocuroniumMerckApproved
85
sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
85
neostigmine/glycopyrrolate + sugammadexMerckApproved
85
sugammadexMerckPhase 3
77
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
77
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
85
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
85
Sugammadex + NeostigmineMerckApproved
85
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
85
sugammadex + Neostigmine + GlycopyrrolateMerckApproved
85
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
85
Rocuronium Bromide + Rocuronium BromideMerckApproved
85
Rocuronium (moderate NMB) + Rocuronium (deep NMB)MerckPre-clinical
23

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85